A novel class of tetrazole-derived Kv1.5 blockers is disclosed. In in vitro studies, several compounds had IC(50)s ranging from 180 to 550 nM. In vivo studies indicated that compounds 2f and 2j increased right atrial ERP about 40% without affecting ventricular ERP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2006.09.021 | DOI Listing |
Publication Analysis
Top Keywords
vivo studies
8
kv15 blockers
8
discovery vitro/in
4
vitro/in vivo
4
studies tetrazole
4
tetrazole derivatives
4
derivatives kv15
4
blockers novel
4
novel class
4
class tetrazole-derived
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!